Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.21+0.05 (+1.20%)
Close on Nov 13, 2026Market cap $449.08MP/E –Yield –
Relmada Therapeutics cash
Cash and short-term investments held at the end of each period.
Relmada Therapeutics's cash was $202.12M at Sep 30, 2026. For fiscal 2025 it was $93.01M, up 107.1% from the year before. Over ten years it grew 48.6% a year on average. The highest annual figure on record is $211.91M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.01M | +107.1% |
| FY2024 | Dec 31, 2024 | $44.91M | -53.4% |
| FY2023 | Dec 31, 2023 | $96.32M | -35.1% |
| FY2022 | Dec 31, 2022 | $148.32M | -30.0% |
| FY2021 | Dec 31, 2021 | $211.91M | +2199.2% |
| FY2019 | Jun 30, 2019 | $9.22M | +311.6% |
| FY2018 | Jun 30, 2018 | $2.24M | +30.9% |
| FY2017 | Jun 30, 2017 | $1.71M | -79.9% |
| FY2016 | Jun 30, 2016 | $8.50M | +141.3% |
| FY2013 | Dec 31, 2013 | $3.52M | +98.7% |
| FY2012 | Dec 31, 2012 | $1.77M | +8006.6% |
| FY2011 | Dec 31, 2011 | $21.87K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $202.12M | +1355.5% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $217.73M | +955.9% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $233.96M | +764.6% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $93.01M | +107.1% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $13.89M | -74.3% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $20.62M | -70.7% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $27.06M | -67.6% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $44.91M | -53.4% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $54.12M | -49.1% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $70.44M | -40.6% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $83.61M | -36.9% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $96.32M | -35.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $106.27M | -42.3% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $118.53M | -46.3% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $132.44M | -37.5% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $148.32M | +68.4% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $184.15M | +68.8% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $220.65M | +114.8% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $211.91M | +2199.2% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $88.09M | +4188.9% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $109.07M | +4394.4% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $102.70M | +11472.3% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $9.22M | +311.6% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $2.05M | -51.8% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $2.43M | -59.1% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $887.49K | -81.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $2.24M | +30.9% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $4.26M | +54.5% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $5.94M | +26.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $4.68M | -24.7% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $1.71M | -79.9% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $2.76M | -75.7% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $4.71M | -68.8% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $6.22M | -67.5% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $8.50M | +141.3% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $11.35M | +183953.8% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $15.13M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $19.17M | – |
| Q4 FY2013CQ4 2013 | Dec 31, 2013 | $3.52M | – |
| Q1 FY2013CQ1 2013 | Nov 30, 2013 | $6.17K | – |
See a number that looks wrong?